Associations - KEAP1 mutation

BIOMARKER:

KEAP1 mutation

Entrez ID:

9817

Related biomarkers:

Mutation

CNA

Others

‹

›

KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: B - Late Trials durvalumab Resistant : B
KEAP1 mutation KEAP1 mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	TAK-228 Sensitive: C2 – Inclusion Criteria TAK-228 Sensitive : C2
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
KEAP1 mutation KEAP1 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KEAP1 mutation KEAP1 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KEAP1 mutation KEAP1 mutation	Solid Tumor Solid Tumor	IPN60090 Sensitive: C3 – Early Trials IPN60090 Sensitive : C3
KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KEAP1 mutation KEAP1 mutation	Lung Adenocarcinoma LUAD	DRP-104 Sensitive: D – Preclinical DRP-104 Sensitive : D
KEAP1 mutation KEAP1 mutation	Lung Cancer Lung Cancer	IPN60090 Sensitive: D – Preclinical IPN60090 Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES